Search

Corbett Worldwide Healthcare Communications Selected as Agency of Year, Cat. II

August 2nd, 2008 by admin

If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

CHICAGO, April 28 /PRNewswire/ — Corbett Worldwide Healthcare Communications has been selected as Agency of the Year in Category II by Med Ad News, reaffirming the Agency’s winning strategy of identifying and pursuing enlightened clients who appreciate the impact of “fresher” ideas for their brands.
The announcement was made at the 19th Annual Manny Awards recently held in New York City at the Sheraton New York Hotel and Towers.
“This award recognizes our team’s hard work and dedication to work with delighted clients and deliver double-digit growth,” said Elaine Eisen, President of Corbett. “We are honored and humbled by this recognition.”
Every year, Med Ad News honors pharmaceutical and healthcare advertising agencies that have demonstrated significant growth and contribution to the industry they serve. Med Ad News is one of the leading publications that provide insight into successful business and marketing strategies. Established in 1982, Med Ad News was acquired in 2007 by Canon Communications LLC and merged into The Canon Communications Pharmaceutical Media Group. The Manny Awards, which is one of the longest running awards programs in the industry, drew more than 600 industry peers at the event. Category II is the designation given to those agencies with annual revenues of $10 to $50 million.
Med Ad News indicated that in 2007, Corbett recorded three global agency-of-record wins along with several blockbuster brand assignments. Their strategic approach to new business development — coupled with strong organic growth — helped the agency deliver a double-digit increase in revenues. Additionally, Corbett amassed 20 creative awards in 2007, including IN AWE, The Globals, and The Rx Award, an industry-wide acknowledgment of their outstanding creative product and dedication to market-moving results.
Corbett Worldwide Healthcare Communications () is a business unit of Corbett Accel Healthcare Group (), one of the largest healthcare communications companies in the U.S. and a part of Omnicom Group Inc. (). Corbett Accel business units include Corbett Worldwide Healthcare Communications and Surge Worldwide Healthcare Communications, both of which offer professional healthcare advertising, branding and promotion; Iris Global Clinical Trial Solutions; Kinect, a full-service interactive agency; and Accel Health, a promotional medical education agency.
Omnicom is a leading global advertising, marketing and corporate communications company. Omnicom’s branded networks and numerous specialty firms provide advertising, strategic media planning and buying, digital and interactive, direct and promotional marketing, public relations and other specialty communications services to more than 5,000 clients in some 100 countries.
To learn more about Corbett Worldwide, contact Elaine Eisen; Gemma Bolech (SVP, Director of Client Service); or Barbara Jurgens (SVP, Director of Client Service) at .
Corbett Worldwide Healthcare Communications

Posted in Health | No Comments »

Rochester Medical Makes Fortune Small Business Hot List of the Fastest-Growing Firms in America

June 18th, 2008 by admin

STEWARTVILLE, Minn., June 17 /PRNewswire-FirstCall/ — Rochester Medical Corporation has been included on the Fortune Small business (FSB) eighth annual list of the 100 fastest growing, publicly held small companies in the United States. This year Rochester Medical is ranked number 16 on the list, up from number 51 last year.
Methodology: For the eighth annual list, FSB once again asked financial research firm Zacks to rank public companies with revenue of less than $200 million and a stock price of more than $1, based on their percentage growth in earnings, revenue, and stock performance over the past three years.
About FORTUNE Small Business
FSB: FORTUNE Small business is the premier magazine for — and about — small business owners, with the largest audience and rate base in the small business category. Through a partnership with American Express, FSB is distributed 10 times a year and reaches 1 million owners and partners of leading small businesses. With unmatched resources and access to the industry’s most innovative thinkers, FSB delivers best practices, connects small business owners to a community of their peers and arms them with the inspiration and actionable advice they need to succeed. FSB, along with FORTUNE, Money, and the Website CNNMoney.com, is part of The Fortune | Money Group. Time Inc. is a division of Time Warner, a leading media and entertainment company.
About Rochester Medical Corporation
Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and advanced continence care applications. In addition to its full line of silicone Male External Catheters, it sells its drug eluting Infection Control Foley Catheters and Antibacterial Intermittent Catheters in the Hospital and Extended Care Marketplace. The Company markets under its own Rochester Medical(R) brand and under existing private label arrangements.
For further information, please contact Anthony J. Conway, President and Chief Executive Officer of Rochester Medical Corporation at (507) 533-9600. More information about Rochester Medical is available on its website at .
Rochester Medical Corporation

Posted in Health | No Comments »

Euro RSCG Life Announces New Appointments to the Euro RSCG Life Chelsea Leadership Team

June 16th, 2008 by admin

NEW YORK, April 28 /PRNewswire/ — Euro RSCG Life (ERL) announced today key appointments to the leadership team at Euro RSCG Life Chelsea, a healthcare communications agency that combines a commitment to Creative business Solutions(sm) with the unique collaborative culture and interdisciplinary resources of Euro RSCG Life Network’s integrated offering. These new leaders will further enhance Euro RSCG Life Chelsea’s strategic infrastructure and help ERL keep pace with 2007’s outstanding growth and 78% new business win rate.
Industry veteran Bernie Coccia has been appointed President of Euro RSCG Life Chelsea. Formerly a Managing Partner at AgencyRx, a company within the CDM Group of agencies, Bernie was instrumental in doubling the agency’s size. While at AgencyRx, Bernie directed worldwide professional advertising for major pharmaceutical companies such as Novartis, Schering-Plough and Merck. He will be providing strategic leadership on Euro RSCG Life Chelsea client brands as well as overseeing agency growth and vision.
Bernie is a graduate of Boston College with a degree in marketing.
“This is an exciting time to be joining Euro RSCG Life Chelsea and the broader ERL healthcare network,” said Bernie Coccia. “I look forward to doing my part to continue the success this proud agency has achieved over the years.”
Dan Marselle, who has been with ERL since 1999, will be joining Euro RSCG Life Chelsea as the Chief of Operations, working closely with Bernie Coccia and the executive team to manage day-to-day activities at the agency. Marselle’s appointment comes as an addition to his current role leading Euro RSCG Life BlueStar, a successful production company he helped to build from the ground up.
Ed Stapor, in his expanded role within the network, will take on additional responsibilities that include Latin America, parts of APAC, network strategy, promotion and expansion including acquisitions and the launch of a Euro RSCG Life West Coast agency. Ed will retain current business unit responsibilities with the management oversight of Chelsea and Euro RSCG Life Canada.
“The addition of Bernie and Dan to the Chelsea team will provide more depth and experience to service our clients and provide more opportunities for business growth,” said Stapor. “These new appointments affirm our commitment to investing in Chelsea and its success.”
About Euro RSCG Life
Euro RSCG Life aligns the company’s 50 health-focused offices in 30 countries. It creates a single network with over 1,500 employees offering clients comprehensive communications disciplines, including advertising, public relations, event promotion, medical education, digital marketing, direct to patient and consulting services. The network’s client roster includes GlaxoSmithKline, Novartis, Pfizer, sanofi-aventis, Schering-Plough and Wyeth. Euro RSCG Life is part of Euro RSCG Worldwide, a leading global marketing communications agency, and the largest unit of Havas, the world’s fourth-largest communications group (Euronext Paris SA: HAV.Pa).
Contact:
Carrie Yamond
Euro RSCG Life PR
212-367-6943

Euro RSCG Life

Posted in Health | No Comments »

Accuray Wins Innovations in Healthcare(SM) ABBY Award

May 30th, 2008 by admin

SUNNYVALE, Calif., April 30 /PRNewswire-FirstCall/ — Accuray Incorporated , a global leader in the field of radiosurgery, today announced that the company won the Innovations in Healthcare(SM) ABBY Award from the Adaptive business Leaders (ABL) Organization in the “Innovations in Medical/Diagnostics Technology” category.
Out of 74 total nominations — the largest pool of nominees in the Award’s ten-year history — 46 companies were selected as semi-finalists and then further narrowed down to eight finalists in three categories — healthcare delivery, healthcare IT, and medtech. Then CEOs from the eight finalist companies presented to an audience of more than 150 healthcare CEOs and senior executives at the 10th Annual Awards event on April 23, 2008 in Costa Mesa, Calif. The audience then voted for an ABBY Award winner in each category.
“Accuray is a quintessential ABBY winner, because they’ve already proven with their CyberKnife Robotic Radiosurgery System that medical technology can actually lower the cost of providing quality healthcare — and at the same time produce a result that saves time for the patient, not to mention providing a ’scarless’ result,” said Mimi Grant, president of the ABL Organization, which hosted the event and is celebrating its 25th anniversary year.
Accuray’s presentation at the ABBY Awards event focused on the key benefits of CyberKnife radiosurgery over surgery, including non-invasive delivery, outpatient procedure, minimal-to-no side effects and no down time. The presentation also indicated that in some cases CyberKnife radiosurgery can lower the cost of cancer treatment by as much as 50 percent by avoiding the need for surgery.
For 10 years, ABL’s ABBY Awards have recognized organizations that have demonstrated transformative advances in medical devices, diagnostics, therapeutics, information technology and innovative approaches to providing health and coverage, decreasing the numbers of uninsured, and engaging consumers more actively in their healthcare and well-being, all of which reduce the cost of providing healthcare.
Complete event details are available at .

About the Adaptive business Leaders (ABL) Organization:

Celebrating its 25th anniversary year, the Adaptive business Leaders (ABL) Organization’s mission is to help health and technology leaders grow great companies. ABL does this through its monthly, industry-specific Round Tables and frequent Events. In their confidential Round Tables, ABL Members — who are CEOs, Presidents, COOs and Division General Managers — openly seek from and share with each other candid advice, best practices and innovative approaches for capitalizing on market trends and opportunities, in order to assure they are well positioned for business and personal success.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated , based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 125 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit .
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and market acceptance and commercialization of products and services are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Accuray Incorporated

Posted in Health | No Comments »

Nu Skin Enterprises Reports First-Quarter 2008 Results

May 20th, 2008 by admin

PROVO, Utah, May 1 /PRNewswire-FirstCall/ — Nu Skin Enterprises, Inc. today reported first-quarter revenue of $298.1 million, a 9 percent improvement over the prior-year period. Earnings per share for the quarter were $0.21, representing a 31 percent increase compared to the same quarter of 2007. Revenue for the quarter was positively impacted 6 percent by foreign currency fluctuations. Quarterly earnings per share were also negatively impacted approximately $0.05 from the translation of yen denominated debt to U.S. dollars as a result of the yen strengthening from 111.5 at the beginning of the first quarter to 99.7 at the end of the quarter. This expense is reported on the Other Income/Expense line of the company’s income statement.
“We have high expectations for the year and our first-quarter results serve as an important milestone in achieving our 2008 targets for revenue growth, operating income and earnings per share,” said Truman Hunt, president and chief executive officer. “I am particularly pleased with our efforts to improve profitability, which resulted in a 9.2 percent operating margin compared to 6.4 percent in the first quarter of 2007, putting us on track to reach our 10.5 percent operating margin goal for the year.
“It’s also encouraging to see good results in both our nutrition and personal care brands with particularly strong demand for our Galvanic Spa System II and Tru Face Essence skin treatment products. We continued to see strong results in South Korea, the United States, Europe, Hong Kong and Southeast Asia, which offset a decline in Japan. The positive first quarter was also highlighted by a successful distributor convention in South Korea. We look forward to similar conventions in Japan and the Greater China region during the second quarter,” said Hunt.
Regional Results
North Asia. First-quarter revenue in North Asia was $149.4 million, compared to $140.3 million for the same period in 2007, representing 6 percent growth. Regional results were positively impacted approximately 9 percent due to foreign currency fluctuations. Local-currency revenue in Japan was down 10 percent year-over-year, while South Korea’s continued momentum drove a local currency revenue gain of 24 percent. The number of executive distributors in the region was down 2 percent while the number of active distributors was slightly higher than the prior year.
Greater China. Revenue in Greater China was $49.9 million for the first quarter compared to $49.0 million in the prior-year period and was positively impacted approximately 5 percent from foreign currency fluctuations. Hong Kong generated local currency revenue growth of 11 percent while Taiwan was down 2 percent and Mainland China was down 12 percent. The executive distributor count in the region was down 5 percent compared to the first quarter of 2007, while the number of active distributors decreased 11 percent.
Americas. Revenue in the Americas was $50.4 million, a 19 percent increase over the prior-year period. In the United States, revenue improved 18 percent while Canada and Latin America both increased approximately 22 percent. Executive and active distributor counts in the region improved 7 percent and 9 percent, respectively, over prior-year results.
South Asia/Pacific. Revenue in South Asia/Pacific was $25.5 million compared to $23.6 million in the prior year. This improvement was driven by a 9 percent positive impact from foreign currency fluctuations and steady results in most markets. The region’s first-quarter executive count improved 1 percent while active distributors decreased 10 percent, compared to the same period in 2007.
Europe. Revenue from Europe was $22.8 million, a 23 percent improvement over the prior-year period. The region’s results benefited from strong growth in Eastern Europe and were positively impacted approximately 12 percent by foreign currency fluctuations. Executive and active distributor counts in the region increased 23 percent and 18 percent, respectively, compared to the prior-year period.
Operational Performance
The company’s gross margin was 81.8 percent, a 30 basis point improvement over the prior-year period, due in part to lower air freight expenses and stronger foreign currencies. Selling expenses, as a percent of revenue, were 42.9 percent in the first quarter, or 30 basis points higher than the prior-year period, but even sequentially. General and administrative expenses were $88.6 million, or 29.7 percent of sales, compared to $89.0 million, or 32.5 percent of sales in the prior-year period. Foreign currency fluctuations negatively impacted general and administrative expenses by approximately $3.8 million during the quarter.
The company’s income tax rate for the quarter was 37.5 percent. In addition, the company’s cash and short-term investment position at the end of the quarter was $99.5 million while dividend payments during the quarter were $7.0 million.
Outlook
“We are very pleased with our first-quarter results and are confident we can achieve our 2008 business objectives,” stated Hunt. “We believe we are on course to deliver on the targets we outlined in our investor meeting last fall, including improving shareholder value by significantly increasing our earnings per share.
“While we are pleased with growth in nearly all of our markets, we remain focused on Japan, which experienced a greater-than-expected decline. During the first quarter, increased regulatory scrutiny and negative media attention focused on the direct selling industry created environmental challenges. We have solid business initiatives to execute in the second quarter, including the launch of LifePak nano and Tru Face Essence Ultra, both enhanced formulations of two of our top-selling products globally. Strong growth in our other major markets, including South Korea, the United States and Europe, is more than offsetting the decline in Japan,” continued Hunt.
“In addition to our May distributor convention in Japan, we will also be holding a convention in the Greater China region during the second quarter. We believe our recent business initiatives in Mainland China have strengthened our position in this key market.
“Looking at the overall state of our business, our strong product and business initiatives are helping drive growth while our restructuring efforts are leading to more streamlined operations and cost savings. In addition, many socio-economic trends are working in our favor. A softening U.S. economy is encouraging more people to look at our business opportunity as a supplemental income source, while our international presence is allowing us to benefit from favorable currency fluctuations. In short, we are encouraged by the direction of our business and remain confident that 2008 will be a tremendous year for Nu Skin Enterprises,” concluded Hunt.
“Currencies have generally shifted in our favor,” said Ritch Wood, chief financial officer. “Based on our first-quarter results and a forecasted yen rate of 107 to the dollar for the rest of 2008, we are increasing our revenue guidance to $1.21 to $1.22 billion with earnings per share of $1.17 to $1.22. We anticipate second-quarter revenue of $303 to $308 million, assuming a yen exchange rate of 107, and earnings per share in the $0.26 to $0.28 range,” said Wood.
The company’s management will host a webcast with the investment community on May 1, 2008 at 11 a.m. (EDT). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on Nu Skin Enterprises’ website, . An archive of the webcast will be available at this same URL through May 16, 2008.
The Company
Nu Skin Enterprises, Inc. is a global direct selling company operating in 47 markets throughout Asia, the Americas and Europe. The company markets premium-quality personal care products under the Nu Skin(R) brand, science-based nutritional supplements under the Pharmanex(R) brand, and technology-based products and services under the Big Planet(R) brand. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol “NUS.”
Nu Skin Enterprises’ press releases are available online at .
Please note: This press release, particularly the “Outlook” section, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that represent the company’s current expectations and beliefs, including, among other things: (i) management’s belief that it is on track to reach the company’s 10.5 percent operating margin goal for the year as well as its other targets including a significant increase in earnings per share; (ii) management’s expectations for distributor conventions, product introductions, and strategic initiatives; (iii) management’s confidence that 2008 will be a tremendous year and that the company will meet its previously outlined targets; and (iv) management’s revenue and earnings projections for 2008 and the second quarter of 2008 set forth in the “Outlook” section. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to: (a) risks that could adversely impact the company’s operations or financial results in its markets, including its largest market, Japan, such as negative market conditions, foreign currency exchange rate fluctuations, material decreases in executive-level and active distributors, or the company’s failure to execute effective initiatives in these markets; (b) uncertainty regarding the impact on our business of the increased regulatory scrutiny of the direct selling industry in Japan and our efforts to increase distributor compliance efforts in this market; (c) an increase in complaints to consumer protection agencies in Japan regarding the activities of some distributors and the associated risks to our business if such increase results in further regulatory scrutiny; (d) regulatory risks associated with the company’s tools and products, which could inhibit our ability to market a tool or product in a market if it is determined to be a medical device in any market or if our distributors make unauthorized claims that would cause such products to be classified as drugs; (e) continued regulatory scrutiny and investigations in Mainland China, which have from time to time in the past, and could in the future, negatively impact the company’s business, including the interruption of sales activities in stores and the imposition of fines; (f) risks that the direct selling regulations in China are interpreted or enforced by governmental authorities in a manner that negatively impacts the company’s current or planned business model there, including continued delays and uncertainty in the provincial direct selling licensing process, and risk that the implementation of a direct selling model will not result in the anticipated growth of the company’s business in China given the restrictive nature of the direct selling laws; (g) any failure of current or planned initiatives or products to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis; (h) any inability of the company to obtain necessary product registrations for its nutritional and personal care products in a timely manner, increased regulatory scrutiny of nutritional products by regulators or changes in regulatory requirements that impact our products; (i) any failure of the implementation of recent business transformation initiatives to reduce overhead and drive growth; (j) adverse publicity related to the company’s business, products, industry or any legal actions or complaints by distributors or others similar to claims made against some of the company’s competitors; (k) adverse results of tax audits and challenges by foreign tax authorities with respect to the amount of income tax, customs, duties and other amounts owed by the company; and (l) continued competitive pressures in the company’s markets. The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 29, 2008. The forward-looking statements set forth the company’s beliefs as of the date of this release, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
For the First Quarters Ended March 31, 2008 and 2007
(in thousands, except per share amounts)

2008 2007
Revenue:
North Asia $149,434 $140,259
Greater China 49,904 48,953
Americas 50,416 42,319
South Asia/Pacific 25,502 23,586
Europe 22,833 18,523
Total revenue 298,089 273,640

Cost of sales 54,197 50,679

Gross profit 243,892 222,961

Operating expenses:
Selling expenses 127,913 116,438
General and administrative expenses 88,555 88,972
Total operating expenses 216,468 205,410

Operating income 27,424 17,551

Other income (expense), net (5,829) (794)
Income before provision for income taxes 21,595 16,757
Provision for income taxes (8,106) (6,257)

Net income $13,489 $10,500

Net income per share:
Basic $.21 $.16
Diluted $.21 $.16

Weighted average common shares outstanding:
Basic 63,457 65,939
Diluted 64,166 66,811

NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(in thousands)

March 31, December 31,
2008 2007
ASSETS
Current assets:
Cash and cash equivalents $97,537 $87,327
Current investments 1,910 5,225
Accounts receivable 23,938 23,424
Inventories, net 100,836 100,792
Prepaid expenses and other 48,020 49,576
272,241 266,344

Property and equipment, net 87,822 88,529
Goodwill 112,446 112,446
Other intangible assets, net 85,933 86,163
Other assets 138,773 129,761
Total assets $697,215 $683,243

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $22,552 $24,108
Accrued expenses 104,933 115,620
Current portion of long-term debt 33,381 31,441
160,866 171,169

Long-term debt 179,163 169,229
Other liabilities 72,806 67,836
Total liabilities 412,835 408,234

Stockholders’ equity:
Class A common stock 91 91
Additional paid-in capital 211,586 209,821
Treasury stock, at cost (412,791) (413,976)
Retained earnings 553,345 546,832
Accumulated other comprehensive loss (67,851) (67,759)
284,380 275,009
Total liabilities and stockholders’ equity $697,215 $683,243

NU SKIN ENTERPRISES, INC.
Distributor/Preferred Customer Growth by Market

As of As of
March 31, 2008 March 31, 2007 % Increase (Decrease)
Active* Executive Active* Executive Active* Executive

North Asia 324,000 14,938 322,000 15,299 0.6 % (2.4%)
Greater China 137,000 6,140 154,000 6,432 (11.0%) (4.5%)
Americas 162,000 4,627 149,000 4,317 8.7 % 7.2 %
South
Asia/Pacific 62,000 2,138 69,000 2,112 (10.1%) 1.2 %
Europe 62,000 2,244 53,000 1,820 17.0 % 23.3 %

Total 747,000 30,087 747,000 29,980 - 0.4 %

* Active distributors include preferred customers and distributors
purchasing products directly from the company during the quarter.

Nu Skin Enterprises, Inc.

Posted in Health | No Comments »